<h2 id="introduction">Introduction</h2> <p>The landscape of medical device regulation is evolving, with FDA 21 CFR Part 820 serving as a critical framework governing the quality and safety of products...
<h2 id="introduction">Introduction</h2> <p>The landscape of medical device regulation is evolving, with FDA 21 CFR Part 820 serving as a critical framework governing the quality and safety of products entering the market. For Medtech innovators, understanding this regulation transcends mere compliance; it represents a strategic advantage that can accelerate product development and enhance market readiness. As the industry adapts to new inspection processes and harmonization efforts with international standards like ISO 13485, a pressing question emerges: how can companies effectively navigate these complexities to ensure both compliance and innovation? This article explores eight key insights that illuminate the path forward for Medtech firms striving to thrive in a competitive regulatory environment.</p> <h2 id="bioaccess-accelerating-compliance-with-fda-21-cfr-part-820">bioaccess®: Accelerating Compliance with FDA 21 CFR Part 820…